KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Esperion Therapeutics (ESPR) Long-Term Debt Repayments (2018)

Esperion Therapeutics (ESPR) has disclosed Long-Term Debt Repayments for 1 consecutive years, with $153000.0 as the latest value for Q3 2018.

  • For the quarter ending Q3 2018, Long-Term Debt Repayments changed N/A year-over-year to $153000.0, compared with a TTM value of $1.0 million through Dec 2018, changed N/A, and an annual FY2025 reading of $54.9 million, down 73.86% over the prior year.
  • Long-Term Debt Repayments was $153000.0 for Q3 2018 at Esperion Therapeutics, down from $451000.0 in the prior quarter.
  • Across five years, Long-Term Debt Repayments topped out at $451000.0 in Q2 2018 and bottomed at $153000.0 in Q3 2018.